

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 13, 2020

Endo International plc
(Exact Name of Registrant as Specified in Its Charter)

Ireland
(State or other jurisdiction
of incorporation)

001-36326
(Commission File Number)

68-0683755
(IRS Employer
Identification No.)

First Floor, Minerva House, Simonscourt Road
Ballsbridge, Dublin 4, Ireland
(Address of principal executive offices)

Not Applicable
(Zip Code)

Registrant's telephone number, including area code 011-353-1-268-2000

Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Ordinary shares, nominal value \$0.0001 per share

Trading symbol(s)
ENDP

Name of each exchange on which registered
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On January 13, 2020, Endo International plc (the “Company”) intends to make a presentation at the J.P. Morgan Healthcare Conference (the “Presentation”), a copy of which is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The Presentation will also be available on the Company's website at www.endo.com.

The information in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed by the Company with the U.S. Securities and Exchange Commission under the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Investor Presentation of Endo International plc dated as of January 13, 2020
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO INTERNATIONAL PLC

By: /s/ Matthew J. Maletta
Name: Matthew J. Maletta
Title: Executive Vice President,
Chief Legal Officer

Dated: January 13, 2020

*Endo International plc
J.P. Morgan Healthcare Conference*

Paul Campanelli, Chairman, President & CEO
January 13, 2020



Forward Looking Statements

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “interim,” “guidance,” “future projects” or similar expressions are forward looking statements. Because these statements reflect our current projected views, expectations and beliefs concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that the forward looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this presentation. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption “Risk Factors” in Endo’s Form 10-Q, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval (“SEDAR”) and as otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ materially from those expressed in any forward looking statements. The forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.



Our Strategic Priorities

1

Reshape our Organization for Success

- **Simplify** our business through process and technology enhancements
- **Drive** productivity improvements
- **Leverage** the new Endo Culture to develop, retain and attract top talent

2

Build Our Portfolio and Capabilities for the Future

- **Expand** the breadth of our Sterile Injectables portfolio
- **Invest** in the continued growth of our highly focused Specialty portfolio
- **Strengthen** our Generics business portfolio and profile for the future
- **Execute** to flawlessly bring the first injectable treatment for cellulite to market





3

Drive Margin Expansion and De-Lever

- **Drive** EBITDA margin improvement through operational execution and continuous improvements
- **De-lever** 3-4x range over time; committed to a highly disciplined capital allocation approach
- **Accelerate** return to EBITDA dollar growth through smart business development



2019 Accomplishments

1 Reshape Our Organization for Success		<ul style="list-style-type: none">• Continued double-digit growth in Branded Specialty portfolio and Sterile Injectables business (Q3 '19 YTD)• Xiaflex® franchise grew 22% Q3 '19 YTD; Vasostrict® grew 16% Q3 '19 YTD
2 Build Our Portfolio & Capabilities for Future		<ul style="list-style-type: none">• CCH for Cellulite BLA filing accepted by FDA in Nov-19• Launched 14 products in 2019• Successful debt refinancing completed in Mar-19
3 Drive Margin Expansion & De-Lever		<ul style="list-style-type: none">• Settlements to resolve "Track 1" Opioid cases (Cuyahoga and Summit Counties in Ohio) and State of Oklahoma Investigation (January 2020)• Favorable FDA decision to remove vasopressin from the 503B Bulks List
Other Highlights		<ul style="list-style-type: none">• Prevailed in district court ruling defending our Adrenalin® 1ml intellectual property against generic manufacturer

Endo Focused on Core Growth Areas of Sterile Injectables and Specialty Branded Businesses



**Branded
Pharmaceuticals**



**Sterile
Injectables**



**Generic
Pharmaceuticals**



**International
Pharmaceuticals**


**3Q19
YTD
Sales**

International
Pharmaceuticals:
\$87m

Generic
Pharmaceuticals:
\$654m

Branded Pharmaceuticals:
\$630m

Sterile Injectables:
\$778m




**3Q18
YTD
Sales**

International
Pharmaceuticals:
\$108m

Generic
Pharmaceuticals:
\$748m


Branded Pharmaceuticals:
\$633m

Sterile Injectables:
\$671m




Specialty Branded Portfolio Continues to Advance with 18% 3Q YTD Growth

- Strong Specialty Branded portfolio focused on high margin branded products to treat conditions in urology and men's health, orthopedics, endocrinology and bariatric
- Xiaflex® 22% Q3 YTD revenue growth. Strong market expansion, with room for additional growth in both Peyronie's Disease and Dupuytren's Contracture
- Strong commercial, marketing and distribution capabilities that will be leveraged for planned expansion into medical aesthetics in 2020 or other products




Consumer Activation Strategies Lead to Growth in Xiaflex® for Peyronie's and Dupuytren's Contracture



Source: *Endo analysis of IQVIA Medical Claims data Apr 2017 – April 2019




Preparing for Successful Commercialization of CCH for Cellulite




Sterile Injectables Continue to Deliver with 16% Q3 YTD Growth

- Trusted manufacturer & distributor of Sterile Injectable products to hospital/critical care setting
- On track to exceed \$1bn in FY2019 revenues
- GPOs provide strategic channel access....with hospitals retaining individual formulary and purchasing decision
- Positioned to expand 505(b) (2) products and to grow through expanding Ready-to-Use (RTU) and other higher-value products in hospital setting



Evolving Customer Needs Provide Unique Sterile Injectable Differentiation, Durability, Growth Opportunities and Improve Patient Care



Clinical Trials and Select Pipeline

- CCH for Cellulite PDUFA date Jul. 6, 2020; launch in Q4 '20, if approved
- Vasostrict: Phase 1 label expansion pharmacokinetic study on Plasma clearance of Vasopressin in healthy volunteers
- Planning to launch 15-20 products in 2020 in Sterile Injectables and Generics, 3 launches Jan '20 YTD
- Expect 1st Nevakar launch in late 2020

**Pipeline & Select
FTF/FTM Settlements
Estimated Launches**

~65 ANDAs Filed
w/FDA

~1/2 ANDA's
FTF/FTM

~55 Projects in
Development

Opportunistic
Business
Development

Product	FY'18 IQVIA/Brand Sales	Settlement
CARAFATE® (sucrafate)	~\$282m	Q1 2020 (AG)
DEXILANT® (dexlansoprazole)	~\$1,200m	Confidential terms
AMITIZA® (lubiprostone)	~\$500m	Q1 2021
CIPRODEX® (ciprofloxacin; dexamethasone otic suspension)	~\$470m	2020
KUVAN® (sapropterin)	~\$433m	Q4 2020
GATTEX® (teduglutide)*	~\$350m	Confidential terms

*GATTEX® LTM brand sales as of 6/30/18



Successful Execution on Strategic Priorities to Date, but Journey Continues

- **Significant progress** achieved on our multi-year turnaround plan
- **Focus on continuing to build** our portfolio and capabilities for the future, anchored on Branded Pharmaceuticals and Sterile Injectables
- **Excellence in overall execution** including strong commercial, marketing and distribution capabilities that will be leveraged for expansion into medical aesthetics and other products
- **Continued strong liquidity profile** and disciplined approach against our stated capital allocation priorities





